{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:18:58Z","timestamp":1791357538002,"version":"4.3.1"},"reference-count":90,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"unspecified","delay-in-days":328,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epidemiol Psychiatr Sci"],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"S204579602200066X_sec_a1\">\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Clozapine is licensed for treatment-resistant psychosis and remains underutilised. This may berelated to the stringent haematological monitoring requirements that are mandatory in most countries. We aimed to compare guidelines internationally and develop a novel Stringency Index. We hypothesised that the most stringent countries would have increased healthcare costs and reduced prescription rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S204579602200066X_sec_a2\" sec-type=\"methods\">\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We conducted a literature review and survey of guidelines internationally. Guideline identification involved a literature review and consultation with clinical academics. We focused on the haematological monitoring parameters, frequency and thresholds for discontinuation and rechallenge after suspected clozapine-induced neutropenia. In addition, indicators reflecting monitoring guideline stringency were scored and visualised using a choropleth map. We developed a Stringency Index with an international panel of clozapine experts, through a modified-Delphi-survey. The Stringency Index was compared to health expenditure per-capita and clozapine prescription per 100 000 persons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S204579602200066X_sec_a3\" sec-type=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One hundred twocountries were included, from Europe (\n                      <jats:italic>n<\/jats:italic>\n                      = 35), Asia (\n                      <jats:italic>n<\/jats:italic>\n                      = 24), Africa (\n                      <jats:italic>n<\/jats:italic>\n                      = 20), South America (\n                      <jats:italic>n<\/jats:italic>\n                      = 11), North America (\n                      <jats:italic>n<\/jats:italic>\n                      = 7) and Oceania and Australia (\n                      <jats:italic>n<\/jats:italic>\n                      = 5). Guidelines differed in frequency of haematological monitoring and discontinuation thresholds. Overall, 5% of included countries had explicit guidelines for clozapine-rechallenge and 40% explicitly prohibited clozapine-rechallenge. Furthermore, 7% of included countries had modified discontinuation thresholds for benign ethnic neutropenia. None of the guidelines specified how long haematological monitoring should continue. The most stringent guidelines were in Europe, and the least stringent were in Africa and South America. There was a positive association (\n                      <jats:italic>r<\/jats:italic>\n                      = 0.43,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001) between a country's Stringency Index and healthcare expenditure per capita.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S204579602200066X_sec_a4\" sec-type=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Recommendations on how haematological function should be monitored in patients treated with clozapine vary considerably between countries. It would be useful to standardise guidelines on haematological monitoring worldwide.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1017\/s204579602200066x","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T04:16:51Z","timestamp":1669349811000},"source":"Crossref","is-referenced-by-count":72,"title":["Clozapine haematological monitoring for neutropenia: a global perspective"],"prefix":"10.1017","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1352-4017","authenticated-orcid":false,"given":"Ebenezer","family":"Oloyede","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Blackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eromona","family":"Whiskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3878-2143","authenticated-orcid":false,"given":"Olubanke","family":"Dzahini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhi","family":"Shergill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"MacCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"key":"S204579602200066X_ref34","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12193"},{"key":"S204579602200066X_ref9","doi-asserted-by":"publisher","DOI":"10.1177\/20451253211032053"},{"key":"S204579602200066X_ref46","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2019.267"},{"key":"S204579602200066X_ref79","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-022-00232-0"},{"key":"S204579602200066X_ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196811072791902"},{"key":"S204579602200066X_ref81","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199803)57:3<206::AID-AJH4>3.0.CO;2-Z"},{"key":"S204579602200066X_ref51","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.175.6.576"},{"key":"S204579602200066X_ref23","first-page":"579","article-title":"Guideline for the pharmacotherapy of treatment-resistant schizophrenia. Royal College of Psychiatrists of Thailand","volume":"83","author":"Disayavanish","year":"2000","journal-title":"Journal of the Medical Association of Thailand"},{"key":"S204579602200066X_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90362-9"},{"key":"S204579602200066X_ref61","doi-asserted-by":"publisher","DOI":"10.1093\/schizbullopen\/sgac042"},{"key":"S204579602200066X_ref33","doi-asserted-by":"publisher","DOI":"10.3109\/08039488.2016.1155234"},{"key":"S204579602200066X_ref59","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(22)00188-2"},{"key":"S204579602200066X_ref10","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbab103"},{"key":"S204579602200066X_ref13","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1998.tb141414.x"},{"key":"S204579602200066X_ref30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1176\/ps.47.1.52","article-title":"Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis","volume":"47","author":"Honigfeld","year":"1996","journal-title":"Psychiatric Services"},{"key":"S204579602200066X_ref67","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G396"},{"key":"S204579602200066X_ref43","doi-asserted-by":"publisher","DOI":"10.1177\/089719009000300401"},{"key":"S204579602200066X_ref82","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sby052"},{"key":"S204579602200066X_ref25","doi-asserted-by":"publisher","DOI":"10.1192\/bjb.2018.67"},{"key":"S204579602200066X_ref26","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.187.3.248"},{"key":"S204579602200066X_ref3","doi-asserted-by":"publisher","DOI":"10.1007\/BF00606410"},{"key":"S204579602200066X_ref89","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1017\/S0033291719000369","article-title":"The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies","volume":"50","author":"Xiao-Hong","year":"2020","journal-title":"Psychological Medicine"},{"key":"S204579602200066X_ref50","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09326"},{"key":"S204579602200066X_ref83","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbaa060"},{"key":"S204579602200066X_ref58","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-021-03514-6"},{"key":"S204579602200066X_ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g4798"},{"key":"S204579602200066X_ref4","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.169.4.483"},{"key":"S204579602200066X_ref87","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7182.527"},{"key":"S204579602200066X_ref47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.1987.tb00092.x"},{"key":"S204579602200066X_ref52","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12898"},{"key":"S204579602200066X_ref64","volume-title":"R: A Language and Environment for Statistical Computing","year":"2022"},{"key":"S204579602200066X_ref78","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.16m11152"},{"key":"S204579602200066X_ref84","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-14-102"},{"key":"S204579602200066X_ref31","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16050503"},{"key":"S204579602200066X_ref57","first-page":"1088","article-title":"There is life after the UK clozapine central non-rechallenge database","volume":"47","author":"Oloyede","year":"2021a","journal-title":"Schizoprehnia Buletin"},{"key":"S204579602200066X_ref39","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzv115"},{"key":"S204579602200066X_ref63","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(58)90027-5"},{"key":"S204579602200066X_ref74","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-020-02592-2"},{"key":"S204579602200066X_ref72","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4103\/0019-5545.55097","article-title":"Prescribing practices of clozapine in India: results of a opinion survey of psychiatrists","volume":"51","author":"Shrivastava","year":"2009","journal-title":"Indian Journal of Psychiatry"},{"key":"S204579602200066X_ref28","unstructured":"Hale, T , Petherick, A , Phillips, T and Webster, S (2020) Variation in government responses to COVID-19. Blavatnik school of government working paper 31."},{"key":"S204579602200066X_ref42","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12700"},{"key":"S204579602200066X_ref7","first-page":"303","article-title":"Clozapine treatment and offending: a within-subject study of patients with psychotic disorders in Sweden","volume":"46","author":"Bhavsar","year":"2020","journal-title":"Schizophrenia Bulletin"},{"key":"S204579602200066X_ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2011.10.014"},{"key":"S204579602200066X_ref69","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13224"},{"key":"S204579602200066X_ref71","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1999.60.573"},{"key":"S204579602200066X_ref21","article-title":"An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels","volume":"35","author":"de Leon","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"S204579602200066X_ref90","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1996.01830100104013"},{"key":"S204579602200066X_ref88","volume-title":"Global Health Expenditure Database","year":"2022"},{"key":"S204579602200066X_ref66","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1249071"},{"key":"S204579602200066X_ref24","doi-asserted-by":"publisher","DOI":"10.1080\/15622970510030090"},{"key":"S204579602200066X_ref60","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7067.1262a"},{"key":"S204579602200066X_ref53","doi-asserted-by":"publisher","DOI":"10.1177\/0004867419833166"},{"key":"S204579602200066X_ref85","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000258"},{"key":"S204579602200066X_ref76","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13159"},{"key":"S204579602200066X_ref80","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796022000087"},{"key":"S204579602200066X_ref29","first-page":"22","article-title":"A historical perspective of clozapine","volume":"60","author":"Hippius","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"key":"S204579602200066X_ref86","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13280"},{"key":"S204579602200066X_ref62","first-page":"4515","article-title":"Etiology of incidental asymptomatic neutropenia and prevalence of benign ethnic neutropenia in patients of Chinese ethnicity","volume":"114","author":"Pathak","year":"2009","journal-title":"American Society of Hematology"},{"key":"S204579602200066X_ref17","unstructured":"Datawrapper (2022) Datawrapper. Available at https:\/\/app.datawrapper.de\/ (Accessed 18th March)."},{"key":"S204579602200066X_ref75","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4156"},{"key":"S204579602200066X_ref36","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.177901"},{"key":"S204579602200066X_ref27","doi-asserted-by":"publisher","DOI":"10.1177\/0004867416641195"},{"key":"S204579602200066X_ref12","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2012.12081036"},{"key":"S204579602200066X_ref49","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15r10085"},{"key":"S204579602200066X_ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199307153290303"},{"key":"S204579602200066X_ref8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1176\/ps.47.1.81","article-title":"A centralized system for monitoring clozapine use i British Columbia","volume":"47","author":"Black","year":"1996","journal-title":"Psychiatric services (Washington, DC)"},{"key":"S204579602200066X_ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00127-022-02257-3"},{"key":"S204579602200066X_ref56","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1181"},{"key":"S204579602200066X_ref68","first-page":"1055","article-title":"A Dutch guideline for the use of clozapine","volume":"44","author":"Schulte","year":"2010","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"S204579602200066X_ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1977.tb00224.x"},{"key":"S204579602200066X_ref5","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12742"},{"key":"S204579602200066X_ref22","first-page":"233","article-title":"Blood dyscrasias in clozapine-treated patients in Italy","volume":"85","author":"Deliliers","year":"2000","journal-title":"Haematologica"},{"key":"S204579602200066X_ref41","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11m07244"},{"key":"S204579602200066X_ref14","doi-asserted-by":"publisher","DOI":"10.1177\/0957154X07070335"},{"key":"S204579602200066X_ref11","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation.V2012.1.174.3798251"},{"key":"S204579602200066X_ref19","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2020.1787831"},{"key":"S204579602200066X_ref65","doi-asserted-by":"publisher","DOI":"10.1177\/0706743717720448"},{"key":"S204579602200066X_ref32","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.8.869"},{"key":"S204579602200066X_ref38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03450190018006"},{"key":"S204579602200066X_ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2018.06.070"},{"key":"S204579602200066X_ref15","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-61-5-876"},{"key":"S204579602200066X_ref73","volume-title":"131 Management of Schizophrenia: A National Clinical Guideline","year":"2013"},{"key":"S204579602200066X_ref18","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12233"},{"key":"S204579602200066X_ref77","doi-asserted-by":"publisher","DOI":"10.1503\/jpn.200061"},{"key":"S204579602200066X_ref37","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201700162"},{"key":"S204579602200066X_ref35","doi-asserted-by":"publisher","DOI":"10.1177\/20451253211072341"},{"key":"S204579602200066X_ref54","unstructured":"NICE (2014) Psychosis and schizophrenia in adults: prevention and management. NICE guidelines."},{"key":"S204579602200066X_ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.05.002"},{"key":"S204579602200066X_ref55","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0311-1"},{"key":"S204579602200066X_ref45","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0335-7"}],"container-title":["Epidemiology and Psychiatric Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S204579602200066X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T04:17:11Z","timestamp":1669349831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S204579602200066X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":90,"alternative-id":["S204579602200066X"],"URL":"https:\/\/doi.org\/10.1017\/s204579602200066x","relation":{},"ISSN":["2045-7960","2045-7979"],"issn-type":[{"value":"2045-7960","type":"print"},{"value":"2045-7979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"e83"}}